| Identification of novel herpes simplex virus replicative intermediates by field inversion gel electrophoresis: implications for viral DNA amplification strategies X Zhang, S Efstathiou, A Simmons Virology 202 (2), 530-539, 1994 | 142 | 1994 |
| Identification of novel herpes simplex virus replicative intermediates by field inversion gel electrophoresis: implications for viral DNA amplification strategies X Zhang, S Efstathiou, A Simmons Virology 202 (2), 530-539, 1994 | 142 | 1994 |
| Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms M Nakamori, X Fu, F Meng, A Jin, L Tao, RC Bast, X Zhang Clinical cancer research 9 (7), 2727-2733, 2003 | 99 | 2003 |
| Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype X Fu, X Zhang Cancer research 62 (8), 2306-2312, 2002 | 95 | 2002 |
| A simple and sensitive method for measuring tumor-specific T cell cytotoxicity X Fu, L Tao, A Rivera, S Williamson, XT Song, N Ahmed, X Zhang PloS one 5 (7), e11867, 2010 | 91 | 2010 |
| Neutralizing aptamers block S/RBDACE2 interactions and prevent host cell infection X Liu, Y Wang, J Wu, J Qi, Z Zeng, Q Wan, Z Chen, P Manandhar, ... Angewandte Chemie International Edition 60 (18), 10273-10278, 2021 | 88 | 2021 |
| Induction of strong antitumor immunity by an HSV2based oncolytic virus in a murine mammary tumor model H Li, A Dutuor, X Fu, X Zhang The Journal of Gene Medicine: A crossdisciplinary journal for research on …, 2007 | 86 | 2007 |
| A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus X Fu, L Tao, R Cai, J Prigge, X Zhang Molecular Therapy 13 (5), 882-890, 2006 | 79 | 2006 |
| A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus X Fu, L Tao, R Cai, J Prigge, X Zhang Molecular Therapy 13 (5), 882-890, 2006 | 79 | 2006 |
| Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells X Fu, A Rivera, L Tao, B De Geest, X Zhang Molecular Therapy 20 (2), 339-346, 2012 | 71 | 2012 |
| Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer M Nakamori, X Fu, CA Pettaway, X Zhang The Prostate 60 (1), 53-60, 2004 | 67 | 2004 |
| Virotherapy with a Type 2 Herpes Simplex Virus–Derived Oncolytic Virus Induces Potent Antitumor Immunity against Neuroblastoma H Li, A Dutuor, L Tao, X Fu, X Zhang Clinical cancer research 13 (1), 316-322, 2007 | 66 | 2007 |
| Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity M Nakamori, X Fu, R Rousseau, SY Chen, X Zhang Molecular Therapy 9 (5), 658-665, 2004 | 65 | 2004 |
| High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H X Zhang, MD Alwis, SL Hart, FW Fitzke, SC Inglis, MEG Boursnell, ... Human gene therapy 10 (15), 2527-2537, 1999 | 64 | 1999 |
| High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H X Zhang, MD Alwis, SL Hart, FW Fitzke, SC Inglis, MEG Boursnell, ... Human gene therapy 10 (15), 2527-2537, 1999 | 64 | 1999 |
| Vectors for gene delivery S Efstathiou, SC Inglis, X Zhang US Patent 5,928,913, 1999 | 64 | 1999 |
| Coadministration of a Herpes simplex Virus-2–based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses H Li, Z Zeng, X Fu, X Zhang Cancer research 67 (16), 7850-7855, 2007 | 59 | 2007 |
| Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery X Fu, A Rivera, L Tao, X Zhang International journal of cancer 133 (10), 2483-2492, 2013 | 58 | 2013 |
| Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review L Belkacemi, SX Zhang Journal of Experimental & Clinical Cancer Research 35, 1-14, 2016 | 56 | 2016 |
| Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus X Fu, L Tao, M Li, WE Fisher, X Zhang Clinical cancer research 12 (10), 3152-3157, 2006 | 55 | 2006 |
